Etoposide Export Market Intelligence: India's 237 Suppliers Shipping to 122 Countries — TransData Nexus 2026

Q: Who are the top etoposide exporters from India?

The top etoposide exporters from India are: 1. INTAS PHARMACEUTICALS LIMITED — $4.8M (44.5% market share); 2. FRESENIUS KABI ONCOLOGY LIMITED — $1.9M (17.3% market share); 3. VENUS REMEDIES LIMITED — $988.8K (9.1% market share); 4. MYLAN LABORATORIES LIMITED — $547.6K (5.1% market share); 5. HETERO LABS LIMITED — $467.0K (4.3% market share). Together they account for 80.3% of India's total etoposide export value.

Q: What is the total export value of etoposide from India?

The total export value of etoposide from India is $10.8M USD, recorded across 2,129 shipment transactions from 237 active exporters to 122 destination countries. The average shipment value is $5.1K.

Q: Which countries import etoposide from India?

India exports etoposide to 122 countries worldwide. The top importing countries are: UNITED STATES (23.1% share, $2.5M), NETHERLANDS (9.2% share, $993.3K), FRANCE (6.9% share, $747.3K), COLOMBIA (4.5% share, $485.1K), GERMANY (4.4% share, $475.0K). These five markets account for 48.1% of total export value.

Q: What is the HS code for etoposide exports from India?

The primary HS code for etoposide exports from India is 30049045. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of etoposide exports from India?

The average unit price for etoposide exports from India is $4.05 USD per unit, with prices ranging from $0.01 to $940.17 depending on formulation, packaging, and order volume. The total market is valued at $10.8M across 2,129 shipments.

Q: Which ports handle etoposide exports from India?

The primary ports for etoposide exports from India are SAHAR AIR (16.8% of shipments), SAHAR AIR CARGO ACC (INBOM4) (15.6% of shipments), DELHI AIR (12.1% of shipments), DELHI AIR CARGO ACC (INDEL4) (11.5% of shipments), AHEMDABAD AIR ACC (INAMD4) (6.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of etoposide?

India is one of the world's leading exporters of etoposide due to its large base of 237 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports etoposide to 122 countries, demonstrating 63% global market coverage.

Q: What certifications do Indian etoposide exporters need?

Indian etoposide exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import etoposide from India?

There are 598 registered buyers importing etoposide from India, spread across 122 countries. The repeat buyer rate is 44.6%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top etoposide supplier from India?

INTAS PHARMACEUTICALS LIMITED is the leading etoposide exporter from India with a market share of 44.5% and total export value of $4.8M across 580 shipments. The top 5 suppliers together control 80.3% of total export value.

Suresh Sormare

Etoposide

India Pharmaceutical Trade Intelligence

$10.8M237 Suppliers122 CountriesHS 30049045

ExportsIndia → UNITED STATES23.1%India → NETHERLANDS9.2%

ImportsGERMANY → India$492 UNITED STATES → India$402

#1 Supplier: INTAS PHARMACEUTICALS #1 Buyer: EVERSANA LIFE

Etoposide Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Etoposide to the World

Between 2022 and 2026, India exported $10.8M worth of etoposide across 2,129 verified shipments to 122 countries — covering 63% of world markets in the Oncology segment. The largest destination is UNITED STATES (23.1%). INTAS PHARMACEUTICALS LIMITED leads with a 44.5% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·HS 30049045

Etoposide export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Etoposide export data snapshot — $10.8M · 237 exporters · 122 countriesTransData Nexus · Indian Customs Data

Top Etoposide Exporters from India

237 active exporters · Ranked by export value

View all 237 →

Top Etoposide Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	INTAS PHARMACEUTICALS LIMITED	$4.8M	580	11	44.5%
2	FRESENIUS KABI ONCOLOGY LIMITED

Top Countries Importing Etoposide from India

122 destination markets · Ranked by import value

All 122 countries →

Top Countries Importing Etoposide from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$2.5M	23.1%
2	NETHERLANDS	$993.3K	9.2%
3	FRANCE	$747.3K	6.9%
4	COLOMBIA	$485.1K	4.5%
5	GERMANY	$475.0K	4.4%
6	UNITED ARAB EMIRATES	$469.7K	4.3%
7	MEXICO	$429.5K	4.0%
8	POLAND	$395.6K	3.7%
9	THAILAND	$380.7K	3.5%
10	UNITED KINGDOM	$353.6K	3.3%

UNITED STATES is India's largest etoposide export destination, absorbing 23.1% of total exports worth $2.5M. The top 5 importing countries — UNITED STATES, NETHERLANDS, FRANCE, COLOMBIA, GERMANY — together account for 48.1% of India's total etoposide export value. The remaining 117 destination countries collectively receive the other 51.9%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Etoposide to India?

4 origin countries · Total import value: $990

India imports etoposide from 4 countries with a combined import value of $990. The largest supplier is GERMANY ($492, 1 shipments), followed by UNITED STATES and UNITED KINGDOM. All values are from Indian Customs (DGFT) import records.

Countries Supplying Etoposide to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$492	1	49.7%
2	UNITED STATES	$402	4	40.7%
3	UNITED KINGDOM	$83	2	8.4%
4	THAILAND	$12	3	1.2%

GERMANY is the largest supplier of etoposide to India, accounting for 49.7% of total import value. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Etoposide

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, etoposide is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The drug has been available in generic forms for several years, facilitating its widespread use in oncology. Notably, on March 18, 2019, the FDA approved Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). This approval underscores the continued relevance of etoposide in combination therapies. As of March 2026, there are no active FDA import alerts specifically targeting etoposide, indicating compliance with regulatory standards by Indian exporters. The substantial number of active exporters (237) reflects a competitive market, necessitating stringent adherence to FDA regulations to maintain market access.

2EU & UK Regulatory Framework

Within the European Union, etoposide is subject to marketing authorization by the European Medicines Agency (EMA). The EMA has conducted periodic safety assessments, such as the one concluded in November 2023 (PSUSA/00001333/202302), to ensure the drug's continued safety and efficacy. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and monitoring of etoposide. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers, ensuring product quality and safety. Indian exporters must align with these stringent standards to access and sustain their presence in these markets.

3WHO Essential Medicines & Global Standards

Etoposide is included in the World Health Organization's Model List of Essential Medicines, highlighting its critical role in cancer treatment globally. The drug is also subject to international pharmacopoeial standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards is imperative for Indian manufacturers to ensure global acceptance and compliance with international quality benchmarks.

4India Regulatory Classification

In India, etoposide is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, etoposide is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the quality of pharmaceutical exports.

5Patent & Exclusivity Status

The primary patents for etoposide have expired, leading to the availability of multiple generic versions and fostering a competitive market landscape. This generic competition has contributed to the drug's affordability and accessibility, both domestically and internationally.

6Recent Industry Developments

In November 2023, the EMA concluded a periodic safety update report (PSUR) assessment for etoposide (PSUSA/00001333/202302), reaffirming its safety profile and therapeutic efficacy. This assessment is crucial for maintaining market authorization within the EU.

In January 2026, the EMA adopted a positive opinion recommending a change to the marketing authorization for Imfinzi (durvalumab), expanding its indications to include combination therapies with etoposide for certain cancers. This development underscores the ongoing integration of etoposide in novel therapeutic regimens.

These developments highlight the dynamic regulatory environment surrounding etoposide, emphasizing the need for continuous monitoring and compliance by Indian exporters to sustain and expand their global market presence.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Etoposide

Retail & reference prices across 9 markets vs. India FOB export price of $4.05/unit

Global Price Benchmark for Etoposide across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$X.XX	USD	According to the FDA's Orange Book, Etoposide is an approved generic drug, which typically results in competitive pricing within the U.S. market.
United Kingdom	$X.XX	GBP	The NHS Drug Tariff lists Etoposide, indicating its availability and regulated pricing within the UK healthcare system.
Germany	$X.XX	EUR	The European Medicines Agency (EMA) has approved Etoposide, and its pricing is subject to the German healthcare system's regulations.
Australia

Supply Chain Risk Assessment — Etoposide

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Etoposide, a critical chemotherapeutic agent, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 70–80% of India's API and KSM requirements are imported from China. Such reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have underscored these risks. For instance, in March 2026, the closure of the Strait of Hormuz due to escalating conflicts led to significant delays in the transportation of raw materials, including those essential for pharmaceutical manufacturing. These events highlight the fragility of supply chains dependent on single-country sources for critical raw materials.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters of Etoposide account for 80.3% of total exports, with INTAS PHARMACEUTICALS LIMITED alone contributing 44.5%. This high supplier concentration poses a significant risk; any operational disruptions within these key companies could severely impact global supply.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. Notably, in November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, which are vital for antibiotic production. While these initiatives are steps toward diversification, their immediate impact on Etoposide's supply chain remains limited.

Access Complete Etoposide Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 2,129 transactions across 122 markets.

Request Demo View Pricing

Frequently Asked Questions — Etoposide Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top etoposide exporters from India?

The leading etoposide exporters from India are INTAS PHARMACEUTICALS LIMITED, FRESENIUS KABI ONCOLOGY LIMITED, VENUS REMEDIES LIMITED, and 12 others. INTAS PHARMACEUTICALS LIMITED leads with 44.5% market share ($4.8M). The top 5 suppliers together control 80.3% of total export value.

What is the total export value of etoposide from India?

The total export value of etoposide from India is $10.8M, recorded across 2,129 shipments from 237 active exporters to 122 countries. The average shipment value is $5.1K.

Which countries import etoposide from India?

India exports etoposide to 122 countries. The top importing countries are UNITED STATES (23.1%), NETHERLANDS (9.2%), FRANCE (6.9%), COLOMBIA (4.5%), GERMANY (4.4%), which together account for 48.1% of total export value.

What is the HS code for etoposide exports from India?

The primary HS code for etoposide exports from India is 30049045. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Etoposide

Etoposide

Top Etoposide Exporters from India

Top Countries Importing Etoposide from India

Who Supplies Etoposide to India?

Quick Facts

Related Oncology

Related Analysis

Need Details?

Regulatory Landscape — Etoposide

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Etoposide

Supply Chain Risk Assessment — Etoposide

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Etoposide Trade Intelligence

Frequently Asked Questions — Etoposide Exports from India

Who are the top etoposide exporters from India?

What is the total export value of etoposide from India?

Which countries import etoposide from India?

What is the HS code for etoposide exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of etoposide exports from India?

Which ports handle etoposide exports from India?

Why is India a leading exporter of etoposide?

What certifications do Indian etoposide exporters need?

How many buyers import etoposide from India?

What is the market share of the top etoposide exporter from India?

Analysis Methodology